BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Rapporto
Tempo reale stimato Cboe BZX  -  18:37 06/07/2022
0.6100 USD   +4.13%
01/07Brooklyn ImmunoTherapeutics, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2022
CI
07/06Brooklyn ImmunoTherapeutics, Inc. annuncia cambiamenti esecutivi
CI
07/06Brooklyn ImmunoTherapeutics, Inc. annuncia cambiamenti nel Consiglio di Amministrazione
CI
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su BROOKLYN IMMUNOTHERAPEUTICS, INC.
01/07BROOKLYN IMMUNOTHERAPEUTICS, INC.: Notice of Delisting or Failure to Satisfy a Continued ..
01/07BROOKLYN IMMUNOTHERAPEUTICS: Quarterly Report (Form 10-Q)
01/07Brooklyn ImmunoTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended ..
01/07BROOKLYN IMMUNOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Co..
01/07BROOKLYN IMMUNOTHERAPEUTICS, INC. - 10-K/A - Management's Discussion and Analysis of Fi..
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell 2500 Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell 2500 Growth Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) added to Russell Microcap Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) added to Russell Microcap Value Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell 2500 Value Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell 2000 Dynamic Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell 2000 Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell 2000 Growth Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell 2000 Value Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell Small Cap Comp Value Inde..
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell Small Cap Comp Growth Ind..
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell 3000 Growth Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell 3000 Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell Small Cap Completeness In..
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from Russell 3000 Value Index
24/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) added to Russell Microcap Growth Index
20/06BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) dropped from S&P Global BMI Index
18/06BROOKLYN IMMUNOTHERAPEUTICS: Investor Presentation
17/06BROOKLYN IMMUNOTHERAPEUTICS: Announces Receipt of Nasdaq Notification Regarding Minimum B..
17/06BROOKLYN IMMUNOTHERAPEUTICS, INC.: Notice of Delisting or Failure to Satisfy a Continued ..
17/06Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum ..
07/06BROOKLYN IMMUNOTHERAPEUTICS, INC.: Change in Directors or Principal Officers (form 8-K)
07/06Brooklyn ImmunoTherapeutics, Inc. Announces Executive Changes
07/06Brooklyn ImmunoTherapeutics Announces Board Changes
07/06Brooklyn ImmunoTherapeutics, Inc. Announces Board Changes
01/06Brooklyn ImmunoTherapeutics Announces Changes to Executive Management
31/05Brooklyn ImmunoTherapeutics Names Matt Angel Interim CEO; Appoints Andrew Jackson as CF..
31/05BROOKLYN IMMUNOTHERAPEUTICS ANNOUNCE: - Form 8-K
31/05BROOKLYN IMMUNOTHERAPEUTICS, INC.: Change in Directors or Principal Officers, Regulation ..
31/05BROOKLYN IMMUNOTHERAPEUTICS ANNOUNCE:  Matt Angel, Ph.D. Appointed Interim Chief Executiv..
31/05Brooklyn Immunotherapeutics Announces Executive Changes
31/05Brooklyn Immunotherapeutics, Inc. Announces Appointment of Andrew Jackson as Chief Fina..
31/05Brooklyn Immunotherapeutics Announces Executive Management Changes
31/05Brooklyn ImmunoTherapeutics, Inc. Announces Board Retirements
27/05BROOKLYN IMMUNOTHERAPEUTICS, INC.: Notice of Delisting or Failure to Satisfy a Continued ..
27/05Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed F..
27/05BROOKLYN IMMUNOTHERAPEUTICS: Announces Receipt of Notice from Nasdaq Regarding Delayed Fi..
21/04Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Fac..
21/04Brooklyn ImmunoTherapeutics, Inc. Announces Establishment of New Research and Developme..
19/04BROOKLYN IMMUNOTHERAPEUTICS, INC.: Changes in Registrant's Certifying Accountant, Financi..
18/04Brooklyn ImmunoTherapeutics Shares Slide After Company Reports Q4 Loss
18/04Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Resul..
15/04BROOKLYN IMMUNOTHERAPEUTICS: Announces Fourth Quarter and Full Year 2021 Financial Result..
15/04BROOKLYN IMMUNOTHERAPEUTICS, INC.: Results of Operations and Financial Condition, Regulat..
15/04Brooklyn ImmunoTherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended..
15/04BROOKLYN IMMUNOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Co..
15/04Brooklyn ImmunoTherapeutics, Inc. Reports Earnings Results for the Full Year Ended Dece..
15/04Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Resul..
31/03NORTH AMERICAN MORNING BRIEFING: Stock Futures -3-
23/03Brooklyn ImmunoTherapeutics, Inc. announced that it has received $11.999999 million in ..
10/03Brooklyn ImmunoTherapeurics Announces Closing of $12 Million Private Placement
09/03BROOKLYN IMMUNOTHERAPEUTICS: Announces Closing of $12 Million Private Placement - Form 8-..
09/03BROOKLYN IMMUNOTHERAPEUTICS, INC.: Entry into a Material Definitive Agreement, Unregister..
07/03Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement
07/03Brooklyn ImmunoTherapeutics, Inc. announced that it expects to receive $11.999999 milli..
24/01BROOKLYN IMMUNOTHERAPEUTICS, INC.: Changes in Registrant's Certifying Accountant, Financi..
20/01BROOKLYN IMMUNOTHERAPEUTICS, INC.: Change in Directors or Principal Officers (form 8-K)
20/01Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board..
20/01Brooklyn ImmunoTherapeutics, Inc. Appoints Erin S. Enright and Heather B. Redman to its..
13/01Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Prope..
05/01BROOKLYN IMMUNOTHERAPEUTICS, INC.: Costs Associated with Exit or Disposal Activities (for..
2021BROOKLYN IMMUNOTHERAPEUTICS, INC.: Change in Directors or Principal Officers (form 8-K)
2021Brooklyn Immunotherapeutics, Inc. Announces Resignation of Luba Greenwood as Director E..
2021Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
2021BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA: BTX) added to NASDAQ Biotechnology Index
2021Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
2021Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index
2021Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
2021Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Qua..
2021Brooklyn ImmunoTherapeutics, Inc. Appoints Susan McClatchey as Head of Quality
1  2  3Succ.
Prossimo evento su BROOKLYN IMMUNOTHERAPEUTICS, INC.